The 2nd Annual Acute Cardiac Unloading and Recovery (A-CURE) Symposium was held in Barcelona, Spain, on August 25, 2017. Over 100 clinical and basic researchers from around the world participated in this year's conference, which was hosted by the A-CURE Working Group. The mission of the A-CURE Working Group is to advance the science and mechanistic understanding of acute cardiac unloading and to support the translation of basic and clinical research into therapies aimed at heart muscle recovery. The last 20 years has seen major technical advances in mechanical circulatory support and research focused on pharmacological means to unload the heart. This progress has enabled new treatment modalities within the clinic for addressing myocardial infarction, cardiogenic shock, acute decompensated heart failure, and advanced heart failure. The goal of these approaches is to unload the heart of its metabolic demand and mechanical workload. Current research indicates that ventricular unloading has profound effects on both cardiac physiology and the cardioprotective processes associated with recovery after damage to the heart has taken place. Clinical and basic researchers from around the world have recognized the potential applications of this new technology to treat and understand several cardiac pathologies. The A-CURE Symposium is the only scientific conference dedicated to advancing the science and clinical application of acute unloading aimed at heart muscle recovery. The A-CURE initiative is expected to grow as the impact of this progressing science advances further into the clinic. This year's keynote address by Dr. Valentin Fuster identified the farreaching impact of myocardial infarction on the development of cardiovascular disease and heart failure. The lectures and abstracts presented during the 2nd annual meeting included basic and translational science and also presented cutting-edge clinical applications of acute unloading. The collection of selected abstracts presented here demonstrates the broad spectrum of research on display at the 2nd Annual A-CURE Symposium.
catheter was inserted into the LA using a trans-septal approach, and the LA pressure-volume loops were continuously monitored during the experiments. Atrial arrhythmia inducibility was examined by rapidly pacing the right atrium. Results: After MI, pigs presented with reduced LV ejection fraction (EF), increased LVEDP, and increased LA volumes. LV unloading with Impella CP resulted in the reduction of the LVEDP, while mean LA pressure and maximum LA volume decreased proportionally to LVEDP. LA pressure-volume loops exhibited a pump-flow dependent left-downward shift. This was associated with a reduced LA active work and improved LA passive stiffness. Prior to Impella, 80% of the pigs were arrhythmia-inducible. However, only 30% of the pigs were inducible after the Impella LV support. Time to spontaneous termination of atrial arrhythmias was significantly shorter with Impella LV support, and this correlated with LA maximum volume as well as with LA active work. LA molecular analysis revealed that NOX2 expression was increased after MI, whereas Impella LV support reduced NOX2 levels together with the reduction in oxidative stress markers. These results suggest that Impella relieves LA stretch and reduces atrial arrhythmogenicity through inhibition of NOX2-dependent oxidative stress. Conclusions: Impella reduces LA pressure, unloads LA, and reduces atrial arrhythmogenicity in a post-MI pig model.
Mechano-Chronotropic Unloading in the Acute Phase of Myocardial Infarction Strikingly Reduces Infarct Size and Prevents Future Heart Failure
Genya Sunagawa, Keita Saku, Takahiro Arimura, Takuya Akashi, Takuya Kishi, Hiroyuki Tsutsui, Kenji Sunagawa Kyushu University Background: Acute myocardial infarction (MI) remains a leading cause of chronic heart failure (CHF). The presence of unsalvaged myocardium leads to cardiac remodeling and CHF. Reducing myocardial oxygen consumption (MVO2) in acute MI is known to reduce infarct size. We reported that the combination of LV mechanical unloading and chronotropic unloading (i.e., bradycardia) synergistically reduced MVO2 more than 60%. In this study, we examined if the combination therapy outperforms mechanical unloading alone in reducing MI size and preventing heart failure in the long-term. We used a transvascular LV assist device (Impella) for mechanical unloading and I f channel inhibitor ivabradine (IVA) for chronotropic unloading. Methods: In 18 anesthetized dogs, we ligated the coronary arteries for 180 min and then reperfused. We initiated Impella or Impella and IVA (1 mg/kg, IV) 60 min after the onset of ischemia and continued the support until 60 min after reperfusion. We allocated animals into three groups: no treatment (IR, n = 6), Impella (n = 6), and Impella + IVA (n = 6). Four weeks after MI, we compared LV function, heart failure parameters, and infarct size. Results: All results were reported in the following order: IR, Impella, and Impella + IVA. In the acute phase of MI, heart rate in Impella + IVA was by far lower than other groups (142 ± 22, 144 ± 16, and 89 ± 13 bpm, p < 0.05, respectively). Four weeks after MI, Impella + IVA normalized LV end-systolic elastance (5.8 ± 2.0, 6.9 ± 1.5, and 13.0 ± 4.6 mmHg/ml, p < 0.05, respectively) and decreased LV end-diastolic pressure (7.7 ± 4.3, 4.4 ± 2.2, and 2.5 ± 2.4 mmHg, p < 0.05, respectively) and NT-proBNP (2858 ± 1412 , 2084 , and 889 ± 499 pg/ml, p < 0.05, respectively). Impella + IVA strikingly reduced the infarct size more than 70% (≈ 1-4.3/15.6) (15.6 ± 4.2, 8.7 ± 3.9, and 4.3 ± 3.4%, p < 0.05, respectively). Conclusions: Combination of LV mechanical unloading and a bradycardic agent synergistically reduced infarct size and prevented subsequent heart failure. This "mechano-chronotropic unloading" may serve as a powerful option to prevent CHF after MI. Background: By design, intra-cardiac left ventricular assist devices (LVADs) support systemic hemodynamics and cardiac output (CO) while decreasing myocardial preload and stroke volume. Hypothesis: Under certain conditions (e.g., partial unloading), LVADsupport could lead to paradoxical increases in the effective arterial elastance (Ea), hindering mechano-energetic unloading. This study tested the hypothesis by assessing the acute effects of LVAD-support on systemic hemodynamics, left-ventricular (LV) mechano-energetics, and oxygen consumption (MVO2) in vivo. Methods: Healthy sheep (n = 12) were instrumented to assess MVO2 (coronary sinus/arterial sampling catheters and LCX coronary flow probe), systemic arterial pressures/CO, and LV pressure-volume relationships. Data before/after LVAD unloading with a continuous flow device (LVAD, n = 8) were compared to those obtained during partial vena cava occlusion (CTRL, n = 8); data were also collected when phenylephrine was administered to restore systemic hemodynamics (CTRL + PE). Heart rate was held constant by atrial pacing. Atrial natriuretic peptide (ANP) production was quantified. Results: Partial LVAD-support (57 ± 4%) decreased LV preload (− 13 ± 2%), filling pressures (− 29 ± 7%), and SV (− 28 ± 5%) and preserved systemic/peak LV pressures (− 3 ± 2%) and CO (− 1 ± 1%). Both the estimated Ea (+ 40 ± 11%) and Ees (+ 33 ± 7%) increased with support. Despite marked reductions in SW (− 29 ± 5%) and PVA (− 31 ± 4%), both coronary flow (− 3 ± 4%) and MVO2 (+ 1 ± 2%) changed negligibly. Complete support (109 ± 9%) decreased LV pressures (− 33 ± 10%), normalizing Ea (− 1 ± 14%) but not Ees (+ 54 ± 12%) with moderate MVO2 reductions (− 13 ± 4%). Unsupported reductions in preload (CTRL) decreased MVO2 (− 39 ± 4%), Qlcx (− 53 ± 4%), and PVA (− 58 ± 4%), while Ea and Ees remained unchanged; pressure support (CTRL + PE) increased Ea and blunted the MVO2 reductions (− 7 ± 2%). LVAD-support altered the MVO2 vs PVA relationship and triggered ANP release. Conclusions: These results suggest that intra-cardiac LVAD-support can trigger mechano-energetic alterations, paradoxically hindering the ability of an LVAD to energetically unload the ventricle. These observations could have important implications in the understanding of myocardial recovery under LVAD-support.
Primary Left Ventricular Unloading Limits Infarct Size by Increasing Myocardial Levels of Stromal Derived Factor One Alpha (SDF1a) in Acute Myocardial Infarction.
Michele Esposito, Xiaoying Qiao, Yali Zhang, Shiva Annamalai, Lara Reyelt, Courtney Boggins, Kevin Morine, Richard H Karas, Navin Kapur Tufts Medical Center Background: Stromal derived factor 1 alpha (SDF1a) is a constitutively expressed cardioprotective chemokine that is rapidly degraded by proteases. We reported that compared to primary reperfusion (PR), first reducing myocardial oxygen demand by activating a transvalvular pump (Impella CP) while delaying coronary reperfusion (primary unloading [PU] ) reduces infarct size in acute myocardial infarction (AMI). Hypothesis: We hypothesize that PU reduces proteolytic degradation of SDF1a thereby increasing SDF1a signaling via the receptor CXCR4 in AMI. Methods: AMI was induced by occlusion of the left anterior descending artery (LAD) for 90 min in male swine (n = 4/group). In the PR group, the LAD was reperfused for 120 min. In the PU group, after 90 min of ischemia, an Impella CP was activated, and the LAD left occluded for an additional 30 min, followed by 120 min of reperfusion. Wholetranscript expression analysis was performed on RNA from the infarct zone using Porcine 1.0 ST microarrays and ConsensusPathDB programs. Quantitative polymerase chain reaction, western blots, and activity assays determined expression and activity of the SDF1a signaling pathway. Sham-operated LV samples served as controls. Results: Compared to PR, PU reduced fibrotic and inflammatory gene expression including reduced transcript levels of matrix-metalloprotease-2 (MMP2), MMP9, and dipeptidyl peptidase-4 (DPP4). Compared to PR, PU increased SDF1a protein levels within the infarct zone. Gel zymography confirmed reduced activity levels of MMP2 and MMP9 within the infarct zone after PU, not PR. Compared to PR, PU attenuated DPP4 protein levels and activity and protein levels of CXCR7, an SDF1a sequestration receptor, within the infarct zone. To explore a functional role for SDF1a in PU, adult male swine received intra-coronary injections of AMD3100, a CXCR4 receptor antagonist, after Impella CP activation. Loss of CXCR4 activity attenuated cardioprotective signaling via Akt, Erk, and GSK3b and increased infarct size compared to vehicle-treated controls. Conclusions: We introduce a novel mechanism by which PU limits proteolytic degradation and CXCR7 mediated sequestration of SDF1a, thereby increasing cardioprotective signaling via SDF1a and overcoming a critical barrier to SDF1a therapeutics in AMI.
Neural Unloading by Intravascular Vagal Nerve Stimulation in Acute Myocardial Infarction Strikingly Reduces Infarct Size and Preserves Cardiac Function Despite Delaying Coronary Reperfusion
Keita Saku, Genya Sunagawa, Takahiro Arimura, Takuya Kishi, Hiroyuki Tsutsui, Kenji Sunagawa Center for Disruptive Cardiovascular Medicine, Kyushu University Background: Although early reperfusion is essential to save lives and prevent subsequent heart failure (HF) in AMI, the door-to-reperfusion time cannot be drastically shortened in the real-world setting. To overcome this limitation, we recently developed intravascular vagal nerve stimulation (iVNS) i.e., neural unloading and demonstrated that iVNS initiated 90 min after the onset of ischemia reduced infarct size by 61% and prevented HF in a dog model of ischemia/reperfusion. However, in the clinical setting, starting iVNS could be much later and introducing iVNS could delay reperfusion. Therefore, we examined the impact of iVNS under a more realistic clinical scenario. We started iVNS very late (180 min after the onset of ischemia), delayed reperfusion by 30 min, and examined its impact 4 weeks later. Methods: In mongrel dogs, we occluded the LAD for 180 min to create ischemia and then reperfused for 60 min (control, n = 6). In iVNS (n = 7) 180 min after the LAD occlusion, we applied iVNS for 60 min and delayed the reperfusion by 30 min (210 min ischemia in total). We increased the intensity of iVNS to the maximum level where hemodynamics remained stable (7.5 ± 2.5 V, 10 Hz). Four weeks after AMI, we compared LV function and infarct size between the control group and dogs treated with iVNS. Results: In comparison with control, despite a 30-min delay in reperfusion (longer ischemic period), iVNS increased LV ejection fraction (47.2 ± 5.4 vs 57.4 ± 4.1%, p < 0.01) and end-systolic elastance (3.8 ± 0.5 vs 10.0 ± 3.4 mmHg/ml, p < 0.01) and decreased LV enddiastolic pressure (17.9 ± 6.3 vs 4.5 ± 1.8 mmHg, p < 0.01). iVNS more than halved the infarct size (normalized by LV circumferential area, 13.3 ± 2.7 vs 6.1 ± 4.1%, p < 0.01). Conclusions: iVNS initiated after the 180 min of ischemia prevented the worsening of LV function and markedly reduced infarct size despite delaying reperfusion. Therefore, neural unloading may serve as a therapeutic option in the management of AMI. Background: Despite improvements in the management of cardiogenic shock (CS) complicating acute myocardial infarction (AMI), mortality remains unreasonably high. In the IABP-Shock II Trial, intra-aortic balloon counterpulsation did not affect mortality in CS patients. Larger prospective data on hemodynamic support strategies are still lacking. Methods: We investigated 154 consecutive patients with CS between January 2013 and April 2016 who were supported by an Impella for isolated LV support at our department. In order to compare the efficacy of active LV unloading, we focused on patients fulfilling the inclusion/ exclusion criteria of the IABP shock II Trial. Results: Out of 154 consecutive patients, 125 were excluded (shock onset > 12 h, n = 40; ROSC > 30 min, n = 15; withdrawal life support, n = 6; biventricular unloading, n = 49; no intrinsic heart action, n = 10; cerebral deficit, n = 5). Compared to the IABP-Shock II Trial, our cohort (total n = 29; Impella 2.5, n = 4; Impella CP, n = 25 patients, mean age of 63.9 ± 2.2 years) exhibited similar baseline characteristics and a similar severity of CS as assessed by SAPS-II score (50.4 ± 1.6). In our registry, coronary disease state was severe with increased prevalence of prior PCI (44.8%), prior coronary artery bypass grafting (CABG, 17.2%) and a greater amount of patients with out-of-hospital cardiac arrest (55.2%) with return of spontaneous circulation after 14.2 ± 2.5 min. The safety outcome was reasonable as in-hospital re-infarction or thrombosis did not occur in our cohort. In the IABP Shock II Trial, 30-day mortality was 41.3% in the control group and 39.7% in the IABP group. In our patients, however, early usage of Impella was associated with a mortality rate as low as 20.7%. Conclusions: These findings suggest that the Impella platform is a promising device for mechanical hemodynamic support in CS particularly due to AMI. To be able to interpret these findings more accurately, a propensity score matched analysis is needed. Therefore, we collaborated with the UKE Hamburg to perform a propensity score matched analysis in a larger collection of patients. Our registry data highlight the serious challenge of prospective studies to include enough patients to provide the study with sufficient statistical power. The Dan Shock trial is a promising prospective trial which is now extended into Germany (DanGer Shock trial). Background: The use of mechanical circulatory support, including Impella CP and veno-arterial extra corporeal membrane oxygenation (ECMO), is increasing in the treatment of cardiogenic shock (CS) following STEMI. However, studies comparing the technologies are lacking. Hypothesis: A combination of norepinephrine and Impella CP is associated with unloading of the left ventricle (LV) compared to ECMO in a large porcine model of CS. Methods: CS was induced by staged microembolization of the left main coronary artery in 12 female swine. A conductance catheter was placed in the LV for measurement of LV end-diastolic pressure (LVEDP), LV enddiastolic volume (LVEDV), and pressure-volume area (PVA). Arterial lactate levels were obtained at CS and 60 min of mechanical support. Data are presented as medians at CS and as relative percentages of CS at 60 min of support, with 95% confidence intervals. A two-sample Wilcoxon rank-sum test was used to identify differences between Impella CP and ECMO. Results: In Impella CP (n = 6) vs ECMO (n = 6), cardiac output was 2.6 L/min (1.9; 3.2) vs 2.0 L/min (1.8; 3.3) p = 0.2, MAP 31 mmHg (24; 37) vs 35 mmHg (27; 42) p = 0.5, lactate 3.9 mmol/L (2.7; 5. Background: Cardiac arrest (CA) can occur in the cath lab during highrisk percutaneous coronary intervention. While attempting to correct the precipitating cause of CA, several options are available to maintain vital organ perfusion. These include manual chest compressions, often interrupted during the rescue PCI, or a continuously operating percutaneous left ventricular assist device (PLVAD). Methods: Thirty swine (50-60 kg) were studied. The left main-proximal left anterior descending artery was occluded with a coronary balloon. Ventricular fibrillation (VF) was induced, and circulatory support was provided with either manual chest compressions (frequently interrupted) or the Impella™ 2.5 L PLVAD without any concurrent chest compressions. After 12 min, the balloon was deflated to restore coronary flow and defibrillation attempted at 16 min. Primary outcome was 24-h favorable neurological function (CPC 1 or 2), while secondary outcomes included defibrillation success, return of spontaneous circulation (ROSC), and hemodynamics. Results: Manual chest compressions consistently produced higher systolic aortic and right atrial pressures, while Impella resulted in higher diastolic pressures. Coronary perfusion pressure (AoD-RaD) was not different between the manual and Impella-treated animals. Outcome measures consistently favored the Impella-treated group, though the small sample size limited the statistical differences.
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Defib success 6/10 18/20 0.14 ROSC 5/10 16/20 0.12 24-hr CPC 1 or 2 0/10 7/20 0.06 " Conclusion: Impella without chest compressions provides adequate hemodynamic support to resuscitate the majority of those suffering CA in the cath lab. Studies regarding the safety, hemodynamic efficacy, and outcome results with combining manual chest compressions and Impella will further elucidate the optimal approach for these patients.
Inhaled Nitric Oxide Supports Myocardial Recovery Following Impella-Based Resuscitation
Andreas Ebeling, R. Zayat, A. Brücken, M. Fries, M. Derwall Hosptial RWTH Aachen Background: We have previously shown that survival after cardiac arrest can be improved by hemodynamically stabilizing a patient during CPR by using the minimally invasive left ventricular assist device, Impella 2.5 (iCPR). We have also demonstrated that the use of inhaled nitric oxide during iCPR leads to increased coronary perfusion, likely thru combined increased coronary pressure and iNO-dependent vasodilation. However, the role of iNO during Impella-supported myocardial recovery post-CPR is less clear. Hypothesis: iNO fosters myocardial recovery by lowering pulmonary vascular resistance (PVRI). Methods: Following electrically induced cardiac arrest and 9 min of untreated VF, eight pigs received iCPR and ventilation with an fiO 2 of 1.0. At 1-h post return of spontaneous circulation (ROSC) and continuing for 5 h, animals inhaled oxygen at an fiO 2 of 0.3 mixed with either 20 ppm iNO (n = 4, iNO) or nitrogen (n = 4, control). Hemodynamic parameters were determined using indwelling arterial and venous catheters.
Results: There were no significant differences regarding mean arterial pressure at baseline (BL), 10 min, 3 h, and 6-h post-ROSC iNO vs control, mmHg 98 ± 9 vs 92 ± 14; 76 ± 15 vs 90 ± 11; 76 ± 11 vs 83.3 ± 12.1; 76 ± 23 vs 75 ± 10). No differences were observed in Impella pump flow (10 min, 1.87 ± 0.2 L/min vs 2.2 ± 0.1; 1 h, 2.2 ± 0.1 vs 2.3 ± 0; 3 h, 2 ± 0.4 vs 2.3 ± 0.1; 5 h, 1.4 ± 0.2 vs 1.3 ± 0.3). Cardiac output was significantly higher during application of iNO, (BL, 7.1 ± 1.3 l/min vs 8.0 ± 0.4; 10 min, 8.4 ± 1.3 vs 8.7 ± 0.9; 3 h, 4.3 ± 0.8 vs 8.9 ± 2.5, p = 0.01; 6 h, 4.3 ± 0.9 vs 5.1 ± 2.2). This difference was not present after weaning from iNO. No significant difference in mean pulmonary arterial pressure (MPAP) among groups were observed at any time point. In contrast, pulmonary vascular resistance (PVR) was significantly reduced during the application of iNO (BL, 97 ± 14 dyn*sec*cm − 5 vs 65 ± 40; 10 min, 118 ± 48 vs 63 ± 28; 3 h, 381 ± 170 vs 44 ± 34, p = 0.004; 6 h, 278 ± 46 vs 274 ± 215). Conclusion: Combining iCPR with iNO enhances the functional recovery of the heart in part by decreasing PVR without altering MPAP. Further echocardiographic studies are warranted to investigate the effects of iNO on myocardial contractility and unloading in this setting.
Servo Controlled Sympathetic Unloading Markedly Augments Volume Tolerance and Instantly Resolves Pulmonary Congestion in Acute Heart Failure
Takeshi Tohyama, Keita Saku, Kazuya Hosokawa, Kamada Kazuhiro, Takuya Kishi, Hiroyuki Tsutsui, Kenji Sunagawa Kyushu University Background: Acute heart failure (AHF) excessively activates sympathetic nerve activity (SNA) which, in turn, increases stressed volume and left ventricular-end diastolic pressure (LVEDP), and often leads to hypertension and life-threatening pulmonary edema. Although sympathetic unloading is a reasonable therapeutic option to this pathophysiology, interventions to manipulate SNA without compromising hemodynamics remain unestablished. The purpose of this investigation was to develop a closed-loop neuromodulator which stimulates the carotid sinus (baroreceptor) nerves in response to changes in AP bionic baroreflex system (BBS). We examined if BBS suppresses SNA and rescues pulmonary congestion without inducing devastating hypotension in a rat model of AHF. Methods: In six Sprague-Dawley rats with sino-aortic denervation, we created AHF by myocardial infarction. We attached electrodes to the right carotid bifurcation for neurostimulation and recorded AP and LVEDP. We servo controlled AP using BBS. In a volume tolerance study, we infused donated blood (0 to 10 ml/kg) stepwise. We compared AP and LVEDP between BBS and sham stimulation (SHAM). In the treatment study, we infused volume (10 ml/kg) and created acute pulmonary congestion. We activated the BBS and compared major hemodynamic responses with baseline. Results: In the volume tolerance study, BBS reduced volume dependence of AP (11.0 ± 3.5 vs 5.5 ± 2.1 mmHg/ml/kg, p < 0.05) and LVEDP (3.72 ± 1.15 vs 2.48 ± 1.10 mmHg/ml/kg, p < 0.05) compared to SHAM, indicating marked improvement of volume tolerance. In the treatment study, BBS instantly suppressed SNA (− 49.5 ± 2.1%) and lowered LVEDP (20.5 ± 5.1 vs 10.8 ± 4.8 mmHg, p < 0.05), while excessively high AP returned toward the normal level (165.3 ± 14.0 vs 119.7 ± 8.8 mmHg, p < 0.05). The physiological AP was achieved by the servo-mechanism of BBS. The settling time (80% of maximum response) of LVEDP was extremely brief (5.2 ± 1.2 s). Conclusions: BBS markedly improves volume tolerance and instantly (within seconds) resolves pulmonary congestion in AHF model rats. BBS may serve as a novel therapeutic strategy via sympathetic unloading for AHF.
PTEN Inhibition with VO-OHPIC Ameliorates Myocardial Ischemia-Reperfusion Injury Mediated by RISK Pathway Activation-Mediated Reduction of Apoptosis: An In Vitro and In Vivo Study
Carlos Santos-Gallego, Kiyotake Ishikawa, Belen Picatoste, Ida Unhammer, Shin Watanabe, Torsten P. Vahl, Javier Sanz, Jagat Narula, Roger J. Hajjar, Valentin Fuster, Juan J. Badimon.
Mt. Sinai Hospital
Background: Mechanical unloading of the LV during STEMI reduces MI size; however, additional cardioprotective strategies complementary to unloading could even further decrease the size of MI. RISK pathway is the main cardioprotective pathway against ischemia reperfusion (IR) injury, and it starts with the phosphorylation (activation) of Akt. Phosphatase and tensin homolog deleted on chromosome ten (PTEN) is a primary phosphatase that dephosphorylates (deactivates) Akt. Hypothesis: PTEN inhibition using the drug VO-OHPIC ameliorates IR injury using both in vitro and porcine models. Methods: Human AC16 cardiomyocytes underwent hypoxiareoxygenation; PTEN inhibition was achieved genetically (siRNA) or pharmacologically (VO-OHPIC) in the presence or absence of inhibitors of the RISK and SAFE cardioprotective pathways. In vivo IR was induced in pigs by 1-h balloon occlusion of proximal LAD; VO-OHPIC was administered 15 min pre-reperfusion. Ten pigs were sacrificed at 1-day post-IR to study mechanisms of cardioprotection. Twelve additional pigs were studied with magnetic resonance and 3D-echocardiography at 1 week and 1-month post-IR to assess cardioprotection and LV remodeling. Results: In vitro, both genetic and pharmacological PTEN inhibition activated RISK (but not SAFE) pathway, increased cell viability, and reduced apoptosis (flow cytometry for annexin-V and caspase-3 activation). The benefits of PTEN inhibition were mediated via RISK activation because they were abrogated with RISK (but not SAFE) inhibitors. In short-term porcine experiments, PTEN inhibition activated RISK pathway, decreased cardiomyocyte apoptosis (TUNEL 17.1 ± 14.6 vs 44.3 ± 8.4, p = 0.02) and oxidative stress, improved mitochondrial function and myocardial energetics, and reduced infarct size (TTC 29.7 ± 2.6 vs 35.5 ± 2.7, p = 0.02). In long-term porcine IR experiments evaluated with cardiac MRI and 3D-echo, PTEN inhibition increased myocardial salvage (29.8 ± 4.4 vs 7.1 ± 3.8, p < 0.01), reduced infarct size (LGE 28.3 ± 1.7 vs 36.7 ± 2.6, p = 0.01), improved both systolic and diastolic function (EF 39.8 ± 4.1 vs 34.5 ± 3.7, p = 0.02; − dP/dt − 917 ± 4.1 vs − 505 ± 49, p = 0.01), and reduced adverse post-infarction cardiac remodeling (LVESV 57.8 ± 19 vs 73.4 ± 11, p < 0.05). Conclusions: PTEN inhibition ameliorates IR injury both using in vitro and in vivo (porcine) models via enhancing the RISK pathway activity.
Impact of Impella Support on Microvascular Perfusion of Cardiac and Major Organs
Shin Watanabe, Olympia Bikou, Kenneth Fish, Lauren Leonardson, Roger J. Hajjar, Kiyotake Ishikawa Mt. Sinai Hospital Background: Impact of Impella on systemic tissue perfusion in a post-MI setting remains poorly characterized. Hypothesis: Impella support will increase tissue perfusion of major organs by increasing the systemic cardiac output. Methods: Myocardial infarction was induced in Yorkshire pigs by occluding the left anterior descending (LAD) artery with a coronary balloon for 60 min followed by thrombus injection using a percutaneous method. Impella support was initiated for 120 min in two pigs immediately after acute myocardial infarction and four pigs 2 weeks after myocardial infarction. Changes in tissue perfusion of the infarct, infarct-border, and remote myocardium, as well as major organ perfusion were assessed by injecting fluorecent microspheres before and 120 min after Impella support. Results: Impella support increased the cardiac output from 3.0 ± 0.5 to 3.5 ± 1.3 L/min. After Impella support for 120 min, infarct perfusion was significantly increased relative to the baseline perfusion (190 ± 89% relative to baseline, p = 0.01). In contrast, perfusion of the infarct border and remote did not show significant changes albeit the numerical increase (infarct border, 121 ± 44%, p = 0.22, remote 134 ± 74%, p = 0.27). Perfusion of the liver, lung, brain, spleen, and kidney also increased numerically; however, significant difference was found only in the brain perfusion (168 ± 36%, p = 0.05). Tissue perfusion of the infarct border, remote, liver, and kidney showed tight correlations, but that of the brain, lung, and spleen did not show significant correlation to any of cardiac and other major organs evaluated. Conclusion: Impella increases infarct and brain perfusion in a pig model of MI. Cardiac non-infarct tissue, liver, and kidney showed similar patterns in the perfusion changes, whereas cardiac-infarcted tissue, brain, lung, and spleen showed independent patterns.
Heterotopic Heart Transplantation in a Mouse Model to Study Mechanical Unloading-Establishment of MEA Measurements to Study Ventricular Arrhythmias Sumi Westhofen, Leonie Dreher, Hermann Reichenspurner, Heimo Ehmke, Alexander Peter Schwoerer.
UHZ Hamburg-Eppendorf
Background: Unloading of failing hearts by assist devices can lead to negative alterations in cardiomyocyte physiology and lead to issues such as ventricular arrhythmias, which is associated with increased mortality and morbidity. Observations in patients and translational animal models indicate that reduction in workload itself induces impaired calcium handling and cellular electrophysiology. Pathophysiological relevance of these alterations is unclear. Hypothesis: Heterotopic heart transplantation (hHTX) in transgenic mice allows detailed studies of pathophysiological alterations of unloading. Since the procedure is technically highly demanding with low error tolerance, it is hardly used. Multielectrode arrays (MEAs) are used to measure extracellular field potentials, up to mainly in brain slices. The establishment in hearts has been shown in rats and cell cultures but hardly in mice. We established MEA investigation of heterotopically transplanted mouse hearts to study electrophysiology and pathophysiology of unloaded cardiac tissue to allow a better understanding of the origin and propagation of the arrhythmic potentials. Methods: The transplantation technique is based on internationally accepted hHTX models in rodents, leading to complete mechanical unloading. Slices of orthotopic and unloaded mouse hearts (300 μm) were cut with a microtome in a Tyrode's solution containing 0.9 mM Ca2 + and BDM (2,3-Butanedione Monoxime), a contraction blocker. They were then transferred into a warm buffer solution without BDM and began to beat spontaneously. A MEA with 64 electrodes was used to measure electrical activity. Conduction velocity, propagation direction, and the QT interval were analyzed. Results: Compared to orthotopic hearts of recipient animals, 14 days of unloading induced weight reduction of the graft by~25%. Slices of orthotopic and unloaded hearts showed intact vitality up to 2 h. In both loaded and unloaded hearts, conduction velocity and QT intervals (range 65 ms-105 ms) could be measured with stable, reproducible results and showed a rate independency in a defined frequency span. Conclusions: We present our first results establishing MEA measurements in unloaded mouse hearts. Our MEA data are reproducible and comparable to published data of action potential durations of adult mice hearts. MEA analysis of heterotopically transplanted mouse hearts is feasible, allowing studies of electrohysiological alterations in unloaded hearts.
LV Unloading Using an Impella CP Improves Coronary Flow and Infarct Zone Perfusion in Ischemic Heart Failure
Olympia Bikou, Shin Watanabe, MD, Kenneth Fish, Lauren Leonardson, Roger J. Hajjar, Kiyotake Ishikawa Mt. Sinai Hospital Background: Increase in coronary flow after an ischemic insult may lead to an efficient delivery of therapeutic materials, such as genes and stem cells. Hypothesis: LV unloading with the Impella CP increases coronary flow and myocardial perfusion (MP) in a sub-acute myocardial infarction (MI). Methods: An anterior transmural MI (infarct size 26.1 ± 4.1%) was induced by occluding the proximal left anterior descending artery for 90 min in Yorkshire pigs (n = 9), followed by a thrombus injection. Two weeks after the MI, six animals underwent LV unloading with an Impella CP for 2 h, whereas three animals underwent vasodilator therapy using sodium nitroprusside (0.24 μg/Kg/h). Epicardial coronary flow by coronary flow wire, ventricular wall stress by pressure catheter and echocardiography, and MP using fluorescent microspheres were assessed. Results: LV support with Impella CP increased total cardiac output (3.0 to 3.5 L/min). Impella significantly reduced end-diastolic volume (106 ± 17 to 89 ± 16 mL, p = 0.02) and end-diastolic pressure (27.6 ± 5.6 to 18.3 ± 6.6 mmHg), resulting in a significant decrease in LV end-diastolic wall stress (infarct zone 71.6 ± 14.7 to 43.3 ± 10.8 kdynes/cm 2 , p = 0.02; remote zone 66.6 ± 20.9 to 40.6 ± 13.3 kdynes/ cm 2 , p = 0.02). Epicardial coronary flow increased acutely and remained elevated after 2 h. Compared to the baseline, MP measured by fluorescent microspheres significantly increased within the infarct zone (+ 109 ± 81%, p = 0.003), which correlated well with the end-diastolic wall stress (r 2 = 0.54, p = 0.006). MP of the remote non-ischemic myocardium did not change significantly (+ 26 ± 74%, p = 0.84). Vasodilator treatment also reduced end-diastolic wall stress; however, epicardial coronary flow only increased transiently. Coronary flow did not increase in one pig that developed severe hypotension (< 60 mmHg). Conclusions: LV unloading using an Impella CP decreased wall stress and increased coronary flow. MP was increased only in the infarct zone and correlated with the change in wall stress. This approach provides new opportunities to mechanically intervene coronary flow and myocardial perfusion after MI.
Predictors of Impella-Induced RV Failure in Post-MI Pigs
Shin Watanabe, Olympia Bikou, Kenneth Fish, Lauren Leonardson, Roger J. Hajjar, Kiyotake Ishikawa Mt. Sinai Hospital Background: Right ventricle (RV) failure becomes apparent after left ventricular assist device (LVAD) implantation in some of the patients with advanced heart failure (HF).
Hypothesis: Temporal left ventricular (LV) support with an Impella after myocardial infarction (MI) can also cause RV failure in a selected patient population. Methods: Myocardial infarction was induced in Yorkshire pigs (20-40 Kg) by percutaneously occluding the left anterior descending (LAD) (n = 18) or the LCx (n = 2). Animals were evaluated for LV and RV function 1-2 weeks after MI using echocardiography and a pressure catheter. Pigs were then implanted with the Impella CP, and the pump flow was increased stepwise. Results: In ten pigs, LV collapsed while RV dilated significantly before reaching the maximum pump support, indicating an appearance of RV failure. Comparison of echocardiographic and hemodynamic parameters before Impella support in pigs with and without RV failure exhibited pulmonary artery acceleration time (102 ± 25 vs 128 ± 27 ms, p = 0.04 and RV failure pigs vs no-RV failure pigs, respectively), tricuspid annular plane systolic excursion (15.6 ± 3.6 vs 18.8 ± 2.4 mm, p = 0.04), LVEF (34.4 ± 10.5 vs 44.0 ± 7.0%, p = 0.03), mean right arterial pressure (5.0 ± 2.9 vs 2.2 ± 1.5 mmHg, p = 0.001), mean RV pressure (6.4 ± 2.0 vs 2.9 ± 2.0 mmHg, p = 0.001), LV maximum pressure (93 ± 18 vs 113 ± 21 mmHg, p = 0.04), LV dP/dt maximum (1204 ± 254 vs 1691 ± 490 mmHg/s, p = 0.01), LV dP/dt minimum (− 1243 ± 274 vs − 1739 ± 450 mmHg/s, p = 0.008), and LV stroke work (2.49 ± 1.36 vs 3.99 ± 1.20 mmHg*L, p = 0.02) as significantly different parameters between the groups. Two LCx infarct pigs did not develop RV failure. Multiple logistic regression analysis revealed mean RV pressure as an independent predictor of RV failure. Conclusion: RV failure was more frequently observed in pigs with worse LV function and those with signs of RV functional impairment after temporal Impella support.
A Mouse Model of Cardiac Recovery
Ana Cruz-Solbes, Keith Youker, Guillermo Torre-Amione, Arvind Bhimaraj Houston Methodist Background: Although the concept of recovery in humans through mechanical circulatory support (MCS) devices has been increasingly recognized, there is no established mouse model to study cardiac recovery from heart failure (HF). We have previously created a non-ischemic mouse model of HF using C57 male mice, NaCl, and L-NAME in drinking water, and surgically implanted angiotensin II infusion pumps in a 5-week protocol. Hypothesis: Recovery after the onset of HF is possible in a non-ischemic mouse model. Methods: We utilized our non-ischemic mouse model and maintained a 3-month recovery phase by removing the angiotensin II pump and returning drinking water to normal. Age-matched control mice were simultaneously followed. Heart weight, fibrosis, and echocardiographic parameters were measured and analyzed in a serial manner. Results: Mice in the HF group had increased fibrosis and heart weight compared to matched controls (p < 0.05), while mice in the recovery group had fibrosis and heart weight comparable to age-matched controls (p = 0.6) with a reduction of the HF phenotype compared to the HF mice (p < 0.05). Also, left ventricular ejection fraction was significantly reduced to below 40% in the HF mice compared to control (p < 0.05), while this parameter seemed to improve back to normal in the recovery group (recovery vs control p = 0.5; recovery vs HF p < 0.05). Fractional shortening was also reduced in the HF mice compared to control (p < 0.05) and returned to normal levels in the recovery mice. Conclusions: We have developed a mouse model of heart failure recovery by documenting the expression and resolution of the HF phenotype using the described protocol. This model will facilitate the study of mechanisms involved in recovery of HF in order to device interventions beyond mechanical unloading for a successful sustained cardiac recovery.
Clinical Investigations Ventricular Unloading by Impella Support Reduces Pulmonary Congestion in Patients with Cardiogenic Shock
Julian Wiora, Angelika Uwarow, Sandra Büter, Christian Jung, Malte Kelm, Ralf Westenfeld, Patrick Horn Universitaetsklinikum Duesseldorf
Background: In patients with cardiogenic shock, pneumonia due to pulmonary congestion and subsequent septic shock is associated with high mortality. Hypothesis: Left ventricular (LV) unloading by a percutaneous left ventricular assist device (pVAD), Impella, in patients with cardiogenic shock reduces pulmonary congestion and the downstream rate of pneumonia. Methods: In this retrospective study, we assessed pulmonary congestion in patients with cardiogenic shock who received the Impella pVAD (n = 30) compared to those who received intra-aortic balloon pump (IABP) support (n = 31). As primary endpoint, pulmonary congestion was assessed by calculating characteristic findings on the chest X-ray using the Halperin score. Scores ranged from 0 to a maximum of 390 points and were assessed in both groups before (pre-) and longitudinally [24 h (day 1), 72 h (day 3)] during support. The rate of pneumonia was assessed as a secondary endpoint. Results: The groups (Impella vs IABP) did not differ in terms of age, SOFA score, Apache score, or basal serum lactate levels. Total fluid balance was calculated as positive during support and did not differ in both groups: + 2.4 ± 0.6 l vs + 1.8 ± 0.4 l at day 1 (p = 0.57), + 1.3 ± 0.7 l vs + 0.6 ± 0.4 l at day 2 (p = 0.86) and + 0.2 ± 0.7 l vs +0.3 ± 0.9 l at day 3 (p = 0.80). Pulmonary congestion as indicated with the Halperin score decreased post-implantation in patients with Impella support (pre 224 ± 14, day 1 178 ± 11, day 3 169 ± 12, p = < 0.01), but it not decrease in patients with IABP support (pre 212 ± 14, day 1 214 ± 10, day 3 206 ± 9, p = 0.42). The incidence of pneumonia did not differ between Impella group (57%, 17/30) and IABP group (74%, 23/31) (p = 0.18). Conclusions: Left ventricular unloading by Impella support reduces pulmonary congestion in patients with cardiogenic shock despite performed positive fluid balance. Therefore, Impella support may facilitate treatment of congestive pneumonia in patients with cardiogenic shock, although prospective trials in larger patient cohorts are required.
Myocardial Mitochondrial ROS Production Is Reduced in the Left Ventricle of Mechanically Unloaded Hearts
Daniel Scheiber, Elric Zweck, Tomas Jelenik, Patrick Horn, Udo Boeken, Diyar Saeed, Malte Kelm, Michael Roden, Julia Szendrödi, Ralf Westenfeld Heinrich-Heine University, Düsseldorf, Germany Background: Increased ventricular filling pressure and volume overload are hallmarks of advanced heart failure (HF). Previous studies have linked pressure and volume overload with alterations in myocardial substrate utilization and mitochondrial energy production in HF. It is well established that mitochondrial production of reactive oxygen species is increased in HF leading to oxidative stress. Mechanical ventricular unloading has been shown to induce protective reverse remodeling in myocardial tissues; however, little is known about the impact of ventricular unloading on myocardial mitochondrial energy metabolism. In this study, we compare mitochondrial reactive oxygen species (ROS) production and respiration in human hearts that were mechanically supported prior to explantation for heart transplantation (HTX) to unsupported hearts. Hypothesis: We hypothesize that (1) chronic left ventricular unloading reduces myocardial mitochondrial ROS production, and (2) improves myocardial mitochondrial oxidative capacity in patients suffering from advanced HF. Methods: We prospectively evaluated 11 patients undergoing HTX between October 2016 and May 2017 in this single-center trial. Myocardial tissue specimens were harvested from macroscopically scar-free areas of the left ventricle during heart explantation. Mitochondrial hydrogen peroxide emission was analyzed fluoroscopically in an Oxygraph-2k (OROBOROS INSTRUMENTS, Austria). Mitochondrial oxidative capacity on citrate cycle-derived substrates and fatty acids was analyzed by high-resolution respirometry. Results: Eight patients had left ventricular assist device (LVAD) implantation prior to heart transplantation (LVAD-HTX, age 58.9 years; BMI 27.12.7; six ischemic heart disease and two dilated heart disease (DCM)), and three patients did not receive mechanical circulatory support prior to transplantation (HTX, 49.11 years; BMI 26.57.1; 3*DCM). Myocardial mitochondrial reactive oxygen species (ROS) production was significantly decreased in the LVAD-HTX group compared to the HTX group (1.40 1 vs 0.90 1 pmol/(s*mg); p < 0.0001). There were no differences in either maximal oxidative capacity on fatty acids or citrate cycle-derived substrates, or on uncoupled respiration or mitochondrial coupling efficiency between the groups. Conclusions: These data suggest that ventricular unloading decreases myocardial mitochondrial ROS production in the setting of HF, whereas mitochondrial respiration remains unaffected. This mechanism may reveal a new target of ventricular unloading-dependent cardioprotection.
The Impella Micro-Axial Flow Catheter Is Safe and Effective for the Treatment of Myocarditis Complicated by Cardiogenic Shock: an Analysis from the Global cVAD Registry Shiva Annamali, Michele Esposito, Sudeep Kuchibhotla, Shelley Hall, Theodore Schreiber, William O'Neill, Navin K. Kapur.
Tufts Medical Center
Background: Myocarditis complicated by cardiogenic shock (Myo-CS) remains a complex clinical problem. The use of acute mechanical circulatory support devices for cardiogenic shock is growing. Hypothesis: We explored the clinical utility of Impella trans-valvular micro-axial flow catheters in the setting of Myo-CS. Methods: We retrospectively analyzed data from 21 sites within the cVAD registry, an ongoing multicenter voluntary registry at sites in North America and Europe that have used Impella in patients with myocarditis. Myocarditis was defined by endomyocardial biopsy in 34% (n = 11) or by clinical history without angiographic evidence of coronary disease (n = 23). Results: A total of 34 patients who received Impella support for Myo-CS were identified. Mean age was 42 ± 17 years with 17 males, and a mean left ventricular ejection fraction (LVEF) on admission was 18 ± 10%. Baseline mean cardiac index was 1.8 ± 0.5 L/min/m 2 ; pulmonary capillary wedge pressure was 25 ± 7 mmHg, and right atrial pressure was 22 ± 3 mmHg. Mean lactate was 27 ± 31 mg/dL. Additionally, 32% (n = 11) of patients required intra-aortic balloon pump, and 85% (n = 29) were requiring vasopressor/inotrope therapy prior to Impella placement. The Impella 2.5, CP, and 5.0 were used in 41% (n = 14), 35% (n = 12), and 24% (n = 8), respectively. Impella support was used for a mean duration of 90.56 ± 74.26 h. Mean LVEF improved from admission to discharge among myocarditis patients unsupported with Impella (18 + 10 to 37 + 20%, p = 0.001). Inhospital mortality was 38% (n = 13), and 47% (n = 16) of patients were discharged alive with 94% recovering without need for further device therapy (Figure below) . Conclusions: This is the largest analysis of Impella-supported myocarditis cases to date. The use of the Impella appears to be safe and effective in the settings of myocarditis complicated by cardiogenic shock. Background: Demographics are shifting to an elderly population with more comorbidities, potentially qualifying for mechanical circulatory support (MCS) during high-risk percutaneous coronary intervention (PCI) in order to maintain coronary perfusion pressure and hemodynamic stability. In this cohort, acute kidney injury (AKI) occurs frequently and is associated with increased short-and long-term mortality. Here, we compared clinical feasibility and incidence of AKI during high-risk PCI supported with peripheral VAECMO and Impella, respectively, in a singlecenter observational registry. Hypothesis: Time-to-MCS implementation of Impella MCS is less time consuming and reduces the incidence of AKI compared to peripheral VAECMO during MCS-supported high-risk PCI. Methods: Patients scheduled for elective MCS-supported high-risk PCI were included. All patients were turned down for surgery. Allocation to VAECMO (n = 10) or Impella (n = 11) was quasi random due to sitespecific restrictions on the daily availability of the VAECMO platform. We analyzed PCI success, duration, peripheral complications (combination of inguinal bleeding, AV-fistula, and aneurysma spurium), and contrast-induced nephropathy (CIN) defined as increase in serum creatinin by ≥ 0.3 mg/dl within 48 h. Results: Patient characteristics did not differ with respect to age (years) (VAECMO 72 ± 4 vs Impella 76 ± 3; p = 0.38), prevalence of severely reduced LV-function (70 vs 100%; p = 0.1), diabetes mellitus (40 vs 54%; p = 0.67), GFR (63 ± 6 ml/min vs 69 ± 6; p = 0.503), days of hospitalization (13.6 ± 11.5 vs 12.6 ± 6.2; p = 0.9), and days on intense care unit (7.9 ± 7.4 vs 3.9 ± 3.4; p = 0.25). All patients were successfully revascularized, and the MCS was weaned at the end of the procedure. Device implantation time was significantly shorter in the Impella group (70 ± 21 min vs 48 ± 9; p = 0.029). Likewise, procedure time tended to be shorter in the Impella cohort (170 ± 29 min vs 141 ± 47; p = 0.149). Peripheral vascular complications were equally distributed (3 vs 3; p = 1). Importantly, despite similar risks for CIN as indicated by similar Mehran score (%, 32 ± 6 vs 35 ± 5; p = 0.6) and a similar exposure to contrast medium (270 ± 113 vs 240 ± 85 mL; p = 0.9), Impella-supported PCI was associated with a reduced incidence of CIN (%, (Impella® 9 vs 60; p = 0.02). Conclusions: MCS-assisted high-risk PCI with Impella support is associated with a lower incidence of contrast-induced nephropathy and a shorter time to MCS.
An Inspection of Hypothermic Mechanical Support Preceding Coronary Reperfusion in Patients with a Profound Cardiogenic Shock Complicating Anterior ST-segment Elevation Myocardial Infarction
Makoto Suzuki, Kenichi Hagiya, Ryosuke Higuchi, Itaru Takamisawa, Tetsuya Tobaru, Tetsuya Sumiyoshi, Mitsuaki Isobe Sakakibara Heart Institute Background: We investigated whether pre-PCI procedural hypothermic mechanical support may provide clinical advantages in patients with profound cardiogenic shock complicating anterior STEMI. Methods: Of the 483 consecutive patients treated with PCI for a first anterior STEMI, including 31 patients with aborted sudden cardiac arrest in our database, a total of 37 consecutive patients with an anterior STEMI complicated with profound cardiogenic shock, defined as the presence of hyper-lactic acidemia (serum levels of lactate > 4 mmol/L), treated with mechanical circulatory support were identified. In accordance with a presence or absence of pre-PCI procedural therapeutic hypothermia, a prevalence of impaired myocardial tissue-level reperfusion, defined by angiographic myocardial blush grades 0 or 1 and in-hospital mortality were evaluated as the clinical outcomes. Results: Demographic characteristics revealed the mean age was 70 ± 14 years, 65% male, 41% hypertension, 49% diabetes mellitus, and serum levels of lactate of 7.8 ± 3.9 mmol/L. Median time from symptom onset to PCI was 80 min, and hospital admission to PCI was 52 min. All patients underwent PCI with mechanical circulatory support, and 13 patients were treated with pre-PCI procedural therapeutic hypothermia with a target core temperature of 34°C. Despite a similar achievement of post-PCI procedural TIMI flow grade III, less incidence of impaired myocardial tissue-level reperfusion was found in those with therapeutic hypothermia (38 vs 75%, p = 0.037). Overall in-hospital mortality was 70%, which were composed of 6 patients with therapeutic hypothermia and 20 of 24 without therapeutic hypothermia (46 vs 83%, p = 0.028). A logistic analysis demonstrated pre-PCI procedural therapeutic hypothermia as a potent contributor to in-hospital survival benefits (p = 0.006).
Conclusions: The present study may provide a great possibility for pre-PCI procedural hypothermic mechanical support to ameliorate in-hospital clinical features in patients with a profound cardiogenic shock complicating anterior STEMI. Background: Interleukin-1 is a pro-inflammatory cytokine and a key driver of systemic inflammation in acute heart failure (HF). In murine models, IL-1-driven inflammation acts as a direct cardiosuppressant and blunts the response to pharmacologic isoproterenol stress testing. In humans, plasma C-reactive protein level, a measureable readout of IL-1 activity, correlates with exercise capacity, and IL-1 blockade improves exercise capacity in both systolic and diastolic HF. Hypothesis: We hypothesized that IL-1 blockade improves LV contractility as measured by LV end-systolic elastance in acute HF. Methods: Acute HF patients were randomized to IL-1 blockade with IL-1 receptor antagonist (anakinra) or placebo for 14 days during hospitalization (n = 13) or within 2 weeks post-discharge (n = 40). LV end-systolic elastance was measured non-invasively as the slope of the LV end-systolic pressure-to-volume relationship (i.e., LV endsystolic pressure divided by LV end-systolic volume). bIRNe in LV end-systolic elastance between baseline and 14 days in the placebo and anakinra groups was analyzed with the Wilcoxon rank sum test for within-group change over time.
Results: There were no significant differences between anakinra and placebo patients with respect to age (p = 0.31), gender (p = 0.79), or high-sensitivity C-reactive protein (p = 0.94). Between baseline and 14 days, median % change in LV end-systolic elastance was 12% (IQR, − 7 to 36%) in the anakinra group and 0% in the placebo group (IQR, − 14 to 19%) (p = 0.08 for between-group difference). In the anakinra group, but not the placebo group, LV end-systolic elastance increased significantly (anakinra 0.13 (IQR, − 0.07 to 0.27), p = 0.03 vs baseline; for placebo 0 (IQR, − 0.17 to 0.14), p = 0.90 vs baseline). Pressure-volume area, a measure of myocardial work, did not change in either group (p > 0.19 for anakinra and placebo). Conclusions: In this small pilot study, anakinra significantly increased LV contractility without increasing myocardial work. These results are consistent with the hypothesized mechanism of action for IL-1 blockade in acute heart failure.
Ventricular Unloading by Impella as Bridge to Surgery in a Case of Complicated Myocardial Infarction
Efstratios Katsianos, Georg Wolff, Manuel Stern, Christian Jung, Malte Kelm, Ralf Westenfeld University Hospital Duesseldorf, Department of cardiology Background: Ventricular septal defect (VSD) is a rare but often fatal complication following myocardial infarction (MI). Patients with a ruptured septum usually present with the precipitous onset of hemodynamic compromise. Mortality of infarct-related VSD remains high; however, it varies significantly depending on the timing of surgical repair. Patients who underwent surgery within 7 days of presentation displayed 54% mortality, while delayed repair was associated with reduced mortality (18%). So far, the impact of left ventricular unloading using percutaneous mechanical circulatory support (MCS) on post-MI VSD has not been investigated. Hypothesis: We hypothesized that Impella support may facilitate delayed surgical repair in a patient with cardiogenic shock in acute MI complicated by VSD. Results: Case report: A 57-year-old male presented to the emergency department with angina pectoris for the last 5 days. He appeared diaphoretic in imminent shock (lactate 3.5 mmol/L). The 12-lead ECG revealed ST-elevations (> 2 mm) in the frontal leads (V2-V5). After unsuccessful volume challenge, norepinephrine was started (0.05 μg/kg/min) and increased rapidly during his transfer to the catheterization laboratory (0.2 μg/kg/min). Coronary angiography revealed a complete, subacute occlusion of the proximal left anterior descending (LAD) and corresponding severely reduced left ventricular function with apical and septal akinesia. In light of the further hemodynamic deterioration (lactate 6.5 mmol/L), we performed an oximetry run revealing a VSD (initial Qp:Qs ratio 1:4). The decision was made to postpone surgical repair due to excessive mortality risk. Mechanical circulatory support with Impella CP was inserted, and the patient stabilized over the next days (lactate < 1.5 mmol/L). Nevertheless, intracardiac shunting increased (Qp:Qs ratio 2:3) over time, and a VSD repair with pericardial patch and left ventricular aneurysmectomy reconstruction was performed successfully on day 7. Postoperatively, the patient had an uneventful course and was discharged 15 days postoperatively. Conclusions: This case provides evidence that mechanical circulatory support with Impella may support a strategy of deferred surgery in patients with cardiogenic shock complicated by VSD. Ventricular unloading may create a window for scar formation bridging to secure surgical repair.
Percutaneous Left Atrial Unloading for Prevention of Pulmonary Edema and to Facilitate Ventricular Recovery Under Extracorporeal Membrane Oxygenation Therapy
Alexander Bernhardt, Mathias Hillebrand, MD; Yalin Yildirim, MD; Samer Hakmi, MD; Florian M. Wagner, MD; Stefan Blankenberg, MD; Hermann Reichenspurner, MD, PhD; Edith Lubos, MD University Heart Center Hamburg Background: Left-sided unloading during extracorporeal membrane oxygenation (ECMO) therapy is crucial for the prevention of pulmonary edema and the facilitation of ventricular recovery. We present a case of a 55-year-old male patient under ECMO therapy with preexisting LV thrombus formation in need of ventricular unloading. Methods: We implanted a 21 French TandemHeart Protekt Solo Transseptal cannula into the left atrium (LA) using a trans-septal approach via femoral vein. The cannula was connected to the venous line of the ECMO circulation. A flow probe and a clamp to reduce flow, if necessary, were attached to the LA line. LA flow was adjusted to 900 ml/min under transesoephageal echocardiography (TEE) control to keep the atrial septum in the midline and prevent suction of the inflow cannula.
Results: After 9 days, the ECMO and TandemHeart cannula have to be weaned off stepwise and explanted. The patient was in NYHA class II without neurological sequelae (Cerebral Performance Scale 1). After 3 months, the patient has fully recovered and is working on a daily basis. The LV function is still moderately impaired and the LV thrombus is of the same size. The atrial septum showed no residual defect. Conclusions: Percutaneous transseptal insertion of the TandemHeart cannula incorporated in an ECMO circulation for the prevention of pulmonary oedema and subsequent weaning from extracorporeal circulation was feasible and safe in a patient with cardiogenic shock and LV thrombus.
Isolated Left Ventricular Failure Predicts Poor Outcome in Patients
Receiving Veno-Arterial Extracorporeal Membrane Oxygenation CA den Uil, LS Jewbali, AE Engstrom, AA Constantinescu, NM van Mieghem Erasmus Medical Center Background: Veno-arterial extracorporeal membrane oxygenation (VAECMO) is increasingly and successfully used to assist patients with refractory cardiogenic shock from different causes; however, it is currently not known which patients would benefit most from ECMO support. Hypothesis: Since ECMO may hamper left ventricular unloading and worsen left ventricular pressure/volume relations, the presence of predominant left ventricular failure in patients on VAECMO support may be associated with worse outcome. To study this hypothesis, we investigated outcome according to the presence of isolated left vs isolated right vs biventricular heart failure in patients with refractory cardiogenic shock of different causes. Methods: This single-center study included 132 patients with acute myocardial infarction (20%), acute on chronic heart failure (14%), postcardiotomy (17%), cardiac allograft failure (8%), pulmonary embolism (16%), and acute non-ischemic heart failure (25%). Ventricular function was a priori assessed by transthoracic echocardiography (isolated left (26%), isolated right (22%), or biventricular heart failure (52%)). The primary endpoint was all-cause mortality at 90 days and long-term. Predictors for adverse outcome were identified by univariate and multivariate Cox regression analysis. Results: Median duration of ECMO support was 6 (3-9) days. Ninetyday survival was 51% (isolated LV failure 32% vs isolated RV failure 62% vs biventricular failure 55%, p = 0.04). The main reason for withdrawal of ECMO support in patients with isolated LV failure was formation of extensive LV thrombus. The presence of isolated left ventricular failure was a predictor for 90-day mortality, irrespective of diagnosis and SAVE score. In patients who survived 90 days following ECMO implantation, long-term (4-year) survival was excellent (95%, no difference between subgroups). Conclusions: Isolated left ventricular failure was an independent predictor for dismal 90-day outcome. This finding questions the routine use of VAECMO in patients with refractory pure LV failure. Pure LV ventricular unloading (by means of last-generation dedicated Impella pumps) might be more suitable because these devices reduce afterload, decrease LV volumes, and thus actively unload the ventricle. Background: Little progress has been made lately in cardiogenic shock (CS), and its mortality remains substantial in refractory CS. Hence, the evolving era of mechanical support is promising, although many aspects regarding the management of mechanical unloading remain uncertain.
